Tyrosine kinase inhibitors: What after complete remission of lung cancer?

Stewart, 2004, Cancer mortality surveillance—United States, 1990–2000, MMWR Surveill. Summ., 53, 1 A.L. Association, Lung cancer fact sheet. 4. 〈http://www.lung.org/lung-disease/lungcancer/resources/facts-figures/lung-cancer-fact-sheet.html〉, December 8th 2013, 2014, p. 1. A.C. Society, Cancer Facts and Figures 2014, Atlanta. Gazdar, 2010, Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy, Cancer Metastasis Rev., 29, 37, 10.1007/s10555-010-9201-z Pao, 2010, Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer, Nat. Rev. Cancer, 10, 760, 10.1038/nrc2947 Siegelin, 2014, Epidermal growth factor receptor mutations in lung adenocarcinoma, Lab. Investig., 94, 129, 10.1038/labinvest.2013.147 Perez-Soler, 2010, EGFR TKIs for Advanced NSCLC: practical Questions, Oncology, 24, 5 Forde, 2015, Managing acquired resistance in EGFR-mutated non–small cell lung cancer, Clin. Adv. hematol. Oncol.: HO, 13, 528 K. Richeimer, (2014, February 13), HIgh Frequency of EGFR Mutations Found in Asian Population. High Risk Across All Asian Subgroups. Asmar, 2014, To treat or not to treat: when is adjuvant EGFR TKI therapy appropriate?, CME Chaft, 2011, Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design, Clin. Cancer Res., 17, 6298, 10.1158/1078-0432.CCR-11-1468 Oxnard, 2011, Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib, Clin. Cancer Res., 17, 6322, 10.1158/1078-0432.CCR-11-1080 R.G. Gray, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. in ASCO Annual Meeting Proceedings, 2013. Neal, 2013, Adjuvant molecularly targeted therapy—epidermal growth factor tyrosine kinase inhibition and beyond, Transl. Lung Cancer Res., 2, 411 Hirsh, 2011, Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer, Curr. Oncol., 18, 126, 10.3747/co.v18i3.877